Stocks › BCO
The Brink's BCO
US equityMarket cap rank #2101
$112.90 −$0.87 (-0.76%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $113.58 +0.60%
Open$113.16
Prev close$113.77
Day range$112.59 – $115.80
Volume420.3K
Market cap$4.65B
P/E (TTM)29.7
Dividend yield0.90%
BCO Stock News
Headlines matching The Brink's or the BCO ticker, most recent first.
- Goldman Sachs Maintains The Brink's(BCO.US) With Buy Rating, Cuts Target Price to $141 Negative
- William Blair Maintains The Brink's(BCO.US) With Buy Rating, Announces Target Price $109
- Goldman Sachs Maintains The Brink's(BCO.US) With Buy Rating, Cuts Target Price to $143 Negative
- Goldman Sachs Maintains The Brink's(BCO.US) With Buy Rating, Raises Target Price to $145 Positive
- Truist Financial Maintains The Brink's(BCO.US) With Buy Rating, Announces Target Price $163
- Goldman Sachs Maintains The Brink's(BCO.US) With Buy Rating, Cuts Target Price to $135 Negative
- William Blair Maintains The Brink's(BCO.US) With Buy Rating
- Truist Financial Maintains The Brink's(BCO.US) With Buy Rating
- Truist Financial Maintains The Brink's(BCO.US) With Buy Rating, Announces Target Price $138
- Goldman Sachs Maintains The Brink's(BCO.US) With Buy Rating, Announces Target Price $111
- Truist Financial Maintains The Brink's(BCO.US) With Buy Rating, Maintains Target Price $144
- Truist Financial Maintains The Brink's(BCO.US) With Buy Rating, Announces Target Price $144
- Truist Financial Maintains The Brink's(BCO.US) With Buy Rating, Cuts Target Price to $138 Negative
- Berjaya: CIRCULAR TO THE SHAREHOLDERS IN RELATION TO THE PROPOSED ACQUISITION OF 40,000,000 ORDINARY SHARES OF RM1.00 EACH IN ATLAN HOLDINGS BERHAD (“AHB”) (“AHB SHARES”), REPRESENTING 15.77% EQUITY INTEREST IN AHB, BY BERJAYA CORPORATION BERHAD (“BCO
- Symphony Life: BOLTON BERHAD ("BOLTON" OR "THE COMPANY") - PROPOSED ACQUISITION BY BOLTON BERHAD OF 1,500,000 ORDINARY SHARES OF RM1.00 EACH IN BCOM HOLDINGS SDN. BHD. ("BCOM"), REPRESENTING THE REMAINING 49% OF THE ISSUED AND PAID-UP SHARE CAPITAL OF BCO
No comments yet — be the first to weigh in on BCO.
Sign in to join the discussion.